Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Irritability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    146 result(s) found for: Irritability. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2019-000723-40 Sponsor Protocol Number: 331-201-00148 Start Date*: 2024-06-13
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
    Medical condition: Irritability Associated With Autism Spectrum Disorder (ASD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005387-22 Sponsor Protocol Number: ACP-103-069 Start Date*: 2022-06-27
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
    Medical condition: Treatment of irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000174-11 Sponsor Protocol Number: CN138603 Start Date*: 2017-04-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Subjects with Irritability Associated with Autistic Disorder
    Medical condition: Irritability in Autism Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004899-35 Sponsor Protocol Number: 331-201-00191 Start Date*: 2024-06-13
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Open Label Trial to Evaluate the Long-term Safety and Tolerability of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectru...
    Medical condition: Irritability Associated With Autism Spectrum Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-005111-40 Sponsor Protocol Number: CN138-178 Start Date*: 2017-04-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Flexible- Dosed Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder
    Medical condition: Autistic Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005388-32 Sponsor Protocol Number: ACP-103-070 Start Date*: 2022-07-05
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD)
    Medical condition: Irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000641-23 Sponsor Protocol Number: CNWL/MC/AFT/01 Start Date*: 2015-11-24
    Sponsor Name:Central and North West London NHS Foundation Trust
    Full Title: Aggression Following TBI: Effectiveness of Risperidone (AFTER)-a feasibility RCT.
    Medical condition: aggression and agitation following on from a traumatic brain injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000309-60 Sponsor Protocol Number: 120101 Start Date*: 2016-03-30
    Sponsor Name:Göteborgs universitet
    Full Title: Biochemical and neuropsychological effects on Premenstrual Dysphoric Disorder after acute administration of escitalopram
    Medical condition: Premenstrual Dysphoric Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038604 - Reproductive system and breast disorders 10051537 Premenstrual dysphoric disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006148-20 Sponsor Protocol Number: 071-005 Start Date*: 2009-01-07
    Sponsor Name:GALENpharma GmbH
    Full Title: A vehicle-controlled, investigator-blinded intraindividual comparison to evaluate the safety, tolerability and efficacy of Momegalen rich cream and ointment in patients with hand and foot eczema an...
    Medical condition: hand and foot eczema, mild to moderate psoriasis vulgaris
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005450-18 Sponsor Protocol Number: SPACe2STAR Start Date*: 2021-07-08
    Sponsor Name:Erasmus MC
    Full Title: SPACe 2 STAR : Safety and pharmacokinetics of antipsychotics in children 2. Studying TDM in An RCT
    Medical condition: irritability in autism spectrum disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001320-31 Sponsor Protocol Number: RIS-AUT-JPN-01 Start Date*: 2015-03-27
    Sponsor Name:Janssen Pharmaceutical K.K
    Full Title: A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents with Irritability Associa...
    Medical condition: Autistic disorder in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10003808 Autistic disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000822-37 Sponsor Protocol Number: UM203 Start Date*: 2017-10-30
    Sponsor Name:Asarina Pharma
    Full Title: A phase II, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study investigating efficacy and safety of Sepranolone (UC1010) in patients with PMDD
    Medical condition: Premenstrual dysphoric disorder (PMDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10051537 Premenstrual dysphoric disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001529-41 Sponsor Protocol Number: 0887X1-4596 Start Date*: 2017-06-02
    Sponsor Name:Pfizer Inc.
    Full Title: Prevenar Post-Licensure Safety Study in Russia: Frequency Of Fever Post Vaccination
    Medical condition: Infants from 3 months up to 23 months of age who may benefit from active immunization against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003718-10 Sponsor Protocol Number: 2014RISP-ID01 Start Date*: 2015-09-15
    Sponsor Name:UMCG
    Full Title: A placebo-controlled discontinuation trial of off-label used risperidone in people with intellectual disability
    Medical condition: no specific condition, we will investigate people with intellectual disability who have been using risperidone on an off-label basis for at least one year.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005331-23 Sponsor Protocol Number: SCOUT-015 Start Date*: 2022-06-20
    Sponsor Name:Radius Pharmaceuticals, Inc.
    Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome
    Medical condition: Hyperphagia related behavior associated with Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020710 Hyperphagia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000241-32 Sponsor Protocol Number: NL80290.018.22 Start Date*: 2022-08-08
    Sponsor Name:Amsterdam UMC
    Full Title: Effectiveness of L-serine dietary supplementation in children with a GRIN2B loss-of-function mutation: n-of-1 series
    Medical condition: GRIN2B deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10027424 Metabolic and nutritional disorders congenital HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005346-37 Sponsor Protocol Number: F1D-MC-HGMR Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental ...
    Medical condition: children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061345 Pervasive developmental disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2024-000001-33 Sponsor Protocol Number: C4591048 Start Date*: 2024-02-07
    Sponsor Name:BioNTech SE
    Full Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Children
    Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    23.1 10021881 - Infections and infestations 10084529 2019 novel coronavirus infection LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002542-33 Sponsor Protocol Number: ZYN2-CL-033 Start Date*: 2022-02-22
    Sponsor Name:Zynerba Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndro...
    Medical condition: Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 ge...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022334-92 Sponsor Protocol Number: qmul250510 Start Date*: 2011-01-07
    Sponsor Name:Barts and the London School of Medicine and Dentistry, Queen Mary University of London
    Full Title: Effects of a combination of varenicline and transdermal nicotine patch on post-quitting urges to smoke
    Medical condition: Tobacco dependence (smoking cessation)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:46:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA